FY2017 Earnings Estimate for Aldeyra Therapeutics, Inc. (ALDX) Issued By Cantor Fitzgerald
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Equities researchers at Cantor Fitzgerald decreased their FY2017 earnings estimates for Aldeyra Therapeutics in a report released on Sunday. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will earn ($1.34) per share for the year, down from their prior forecast of ($1.30). Cantor Fitzgerald currently has a “Overweight” rating and a $22.00 target price on the stock.
Several other equities analysts have also commented on ALDX. HC Wainwright set a $18.00 price target on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Thursday, August 10th. ValuEngine lowered shares of Aldeyra Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. Canaccord Genuity reiterated a “buy” rating and issued a $27.00 price target (up from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, September 13th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $14.00 price target (up from $9.00) on shares of Aldeyra Therapeutics in a research note on Thursday, September 14th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Aldeyra Therapeutics has an average rating of “Buy” and an average target price of $17.29.
Aldeyra Therapeutics (NASDAQ:ALDX) opened at $6.05 on Wednesday. Aldeyra Therapeutics has a one year low of $3.80 and a one year high of $11.90. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.35 and a quick ratio of 20.35.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.09.
Several institutional investors and hedge funds have recently made changes to their positions in ALDX. Renaissance Technologies LLC purchased a new position in shares of Aldeyra Therapeutics during the first quarter worth approximately $132,000. Hikari Power Ltd grew its position in shares of Aldeyra Therapeutics by 186.4% during the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after acquiring an additional 70,196 shares during the last quarter. Sphera Funds Management LTD. grew its position in shares of Aldeyra Therapeutics by 31.0% during the second quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock worth $4,117,000 after acquiring an additional 207,431 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Aldeyra Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after acquiring an additional 9,407 shares during the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in shares of Aldeyra Therapeutics during the second quarter worth approximately $104,000. Institutional investors and hedge funds own 40.34% of the company’s stock.
In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the stock in a transaction dated Tuesday, September 19th. The shares were acquired at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 28.40% of the company’s stock.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.